Manufacturers of branded cancer biologics are reducing their prices as a way to hold on to market share, which has limited the potential savings that health plans can realize from biosimilars, according to a study published in Health Affairs . In fact, potential savings from site-neutral payments — which reimburse hospitals at the same rate that physician practices receive — were double the potential savings from biosimilar competition.

“Potential savings will only be realized if major changes occur in market dynamics and insurer strategies,” wrote James C. Robinson, Ph.D., professor of health policy and management at the University of California at Berkeley, and Christopher M. Whaley, Ph.D., associate professor in the Department of Health Services, Policy and Practice at the Brown Un

See Full Page